In 2019, Bristol-Myers Squibb Company and Celgene Corporation announced to the world that they had entered into a definitive acquisition agreement. Bristol-Myers Squibb would acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. It was the largest pharmaceutical acquisition in history.